Amneal Pharmaceuticals In... (AMRX)

Here is how Amneal Pharmaceuticals (AMRX) and ANIXA BIOSCIENCES INC (ANIX) have performed compared to their sector so far this year.

The global healthcare market is growing rapidly—it is expected to climb at a 6.9% CAGR over the next eight years, reaching more than $22.3 trillion by 2033. Its appeal to investors in the current mark...

For my initial rating of Amneal Pharmaceuticals (AMRX), I am calling it a buy. I was impressed by its large, diversified portfolio of therapies across clinical segments, and active pipeline of future ...

The consensus price target hints at a 25.5% upside potential for Amneal (AMRX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate r...

The average of price targets set by Wall Street analysts indicates a potential upside of 27.7% in Amneal (AMRX). While the effectiveness of this highly sought-after metric is questionable, the positiv...

If you are looking for stocks that are well positioned to maintain their recent uptrend, Amneal (AMRX) could be a great choice. It is one of the several stocks that passed through our "Recent Price St...

Amneal (AMRX) Q2 EPS Jumps 56%

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX ) Q2 2025 Earnings Conference Call August 5, 2025 8:30 AM ET Company Participants Anastasios G. Konidaris - Executive VP & CFO Anthony DiMeo - Head of Investo...

While the top- and bottom-line numbers for Amneal (AMRX) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to ...

Amneal Pharmaceuticals (AMRX) came out with quarterly earnings of $0.25 per share, beating the Zacks Consensus Estimate of $0.18 per share. This compares to earnings of $0.16 per share a year ago.